Nathan P Staff1, Nicolas N Madigan2, Jonathan Morris2, Mark Jentoft2, Eric J Sorenson2, Greg Butler2, Dennis Gastineau2, Allan Dietz2, Anthony J Windebank2. 1. From the Departments of Neurology (N.P.S., N.N.M., E.J.S., A.J.W.), Radiology (J.M.), and Laboratory Medicine and Pathology (M.J., G.B., D.G., A.D.), Mayo Clinic, Rochester, MN. staff.nathan@mayo.edu. 2. From the Departments of Neurology (N.P.S., N.N.M., E.J.S., A.J.W.), Radiology (J.M.), and Laboratory Medicine and Pathology (M.J., G.B., D.G., A.D.), Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To determine the safety of intrathecal autologous adipose-derived mesenchymal stromal cell treatment for amyotrophic lateral sclerosis (ALS). METHODS: Participants with ALS were enrolled and treated in this phase I dose-escalation safety trial, ranging from 1 × 107 (single dose) to 1 × 108 cells (2 monthly doses). After intrathecal treatments, participants underwent standardized follow-up, which included clinical examinations, revised ALS Functional Rating Scale (ALSFRS-R) questionnaire, blood and CSF sampling, and MRI of the neuroaxis. RESULTS: Twenty-seven patients with ALS were enrolled and treated in this study. The safety profile was positive, with the most common side effects reported being temporary low back and radicular leg pain at the highest dose level. These clinical findings were associated with elevated CSF protein and nucleated cells with MRI of thickened lumbosacral nerve roots. Autopsies from 4 treated patients did not show evidence of tumor formation. Longitudinal ALSFRS-R questionnaires confirmed continued progression of disease in all treated patients. CONCLUSIONS: Intrathecal treatment of autologous adipose-derived mesenchymal stromal cells appears safe at the tested doses in ALS. These results warrant further exploration of efficacy in phase II trials. CLASSIFICATION OF EVIDENCE: This phase I study provides Class IV evidence that in patient with ALS, intrathecal autologous adipose-derived mesenchymal stromal cell therapy is safe.
OBJECTIVE: To determine the safety of intrathecal autologous adipose-derived mesenchymal stromal cell treatment for amyotrophic lateral sclerosis (ALS). METHODS: Participants with ALS were enrolled and treated in this phase I dose-escalation safety trial, ranging from 1 × 107 (single dose) to 1 × 108 cells (2 monthly doses). After intrathecal treatments, participants underwent standardized follow-up, which included clinical examinations, revised ALS Functional Rating Scale (ALSFRS-R) questionnaire, blood and CSF sampling, and MRI of the neuroaxis. RESULTS: Twenty-seven patients with ALS were enrolled and treated in this study. The safety profile was positive, with the most common side effects reported being temporary low back and radicular leg pain at the highest dose level. These clinical findings were associated with elevated CSF protein and nucleated cells with MRI of thickened lumbosacral nerve roots. Autopsies from 4 treated patients did not show evidence of tumor formation. Longitudinal ALSFRS-R questionnaires confirmed continued progression of disease in all treated patients. CONCLUSIONS: Intrathecal treatment of autologous adipose-derived mesenchymal stromal cells appears safe at the tested doses in ALS. These results warrant further exploration of efficacy in phase II trials. CLASSIFICATION OF EVIDENCE: This phase I study provides Class IV evidence that in patient with ALS, intrathecal autologous adipose-derived mesenchymal stromal cell therapy is safe.
Authors: Ki-Wook Oh; Chanil Moon; Hyun Young Kim; Sung-Il Oh; Jinseok Park; Jun Ho Lee; In Young Chang; Kyung Suk Kim; Seung Hyun Kim Journal: Stem Cells Transl Med Date: 2015-05-01 Impact factor: 6.940
Authors: Dimitrios Karussis; Clementine Karageorgiou; Adi Vaknin-Dembinsky; Basan Gowda-Kurkalli; John M Gomori; Ibrahim Kassis; Jeff W M Bulte; Panayiota Petrou; Tamir Ben-Hur; Oded Abramsky; Shimon Slavin Journal: Arch Neurol Date: 2010-10
Authors: Martin R Turner; Orla Hardiman; Michael Benatar; Benjamin R Brooks; Adriano Chio; Mamede de Carvalho; Paul G Ince; Cindy Lin; Robert G Miller; Hiroshi Mitsumoto; Garth Nicholson; John Ravits; Pamela J Shaw; Michael Swash; Kevin Talbot; Bryan J Traynor; Leonard H Van den Berg; Jan H Veldink; Steve Vucic; Matthew C Kiernan Journal: Lancet Neurol Date: 2013-03 Impact factor: 44.182
Authors: Hung Nguyen; Sydney Zarriello; Alexandreya Coats; Cannon Nelson; Chase Kingsbury; Anna Gorsky; Mira Rajani; Elliot G Neal; Cesar V Borlongan Journal: Neurobiol Dis Date: 2018-09-13 Impact factor: 5.996
Authors: Ajay A Madhavan; Dan Summerfield; Christopher H Hunt; Dong K Kim; Karl N Krecke; Aditya Raghunathan; John C Benson Journal: Neuroradiol J Date: 2020-02-03
Authors: Stephen A Goutman; Masha G Savelieff; Stacey A Sakowski; Eva L Feldman Journal: Expert Opin Investig Drugs Date: 2019-06-12 Impact factor: 6.206
Authors: Stephen A Johnson; Ton Fang; Fabiola De Marchi; Dylan Neel; Donatienne Van Weehaeghe; James D Berry; Sabrina Paganoni Journal: Drugs Date: 2022-09-19 Impact factor: 11.431
Authors: Christopher Duma; Oleg Kopyov; Alex Kopyov; Mark Berman; Elliot Lander; Michael Elam; Michael Arata; David Weiland; Ruslana Cannell; Chad Caraway; Sean Berman; Kristin Scord; Lian Stemler; Karlyssa Chung; Samuel Khoudari; Rory McRory; Chace Duma; Sawyer Farmer; Anthony Bravo; Christian Yassa; Ami Sanathara; Elisa Singh; Benjamin Rapaport Journal: Mol Biol Rep Date: 2019-07-20 Impact factor: 2.316
Authors: Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini Journal: Neurosci Biobehav Rev Date: 2021-06-19 Impact factor: 9.052